MedCity News has partnered with BioCrossroads to provide coverage focused on Indiana’s next generation of growth and innovation in life sciences.
For its biggest fund-raise thus far, Indianapolis-based NICO has brought in $15 million, according to a regulatory filing, with the plan to progress its trial of the BrainPath device. The device is designed to treat spontaneous intracerebral hemorrhage (ICH), which it notes is the deadliest, most debilitating and most expensive category of stroke. Essentially it enables the removal of blood and clots spilled during stroke into difficult-to-reach portions of the brain.
The clinical trial will reportedly take place throughout 10 different centers over a year with patients, each having a 6-month follow up. The new study will be led by The Emory Stroke Center of Emory University hospitals and the Marcus Stroke & Neuroscience Center of Grady Memorial Hospital.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The BrainPath device allows surgeons to explore lesions and examine subcortal portions of the brain without creating too much damage to the other brain tissue. Once the surgery is done, the sheath used with the device can remain present in the brain so that after the obtruator is removed there is still an established access way for further examination if there needs to be additional surgery.
BrainPath was cleared by the FDA last July with a design modification. What was cleared included NICO’s devices’ subcortical access to diseases such as primary or secondary brain tumors, vascular abnormalities or malformations and intraventricular tumors or cysts.
Photo: Flickr user Liz Henry
